Are you afraid of having your blood drawn? But what if the blood test could detect cancer causing genetic mutations and viruses, and allow for early treatment?  

I’m asking this because we are going to look at a company called Lucence, which makes blood tests to detect cancers. 

Founded in 2016, Lucence was spun off from the Agency for Science, Technology and Research (A*STAR). 

It had in 2019 unveiled a blood test called LiquidHALLMARK that detects 14 types of cancers, 50 genetic mutations and two viruses. Lucence had said then that LiquidHALLMARK is the world's first blood test that simultaneously detects both cancer-causing genetic mutations and viruses with 99.9 per cent accuracy.

But how much money does this represent? How does the company assess its competition, and how is it treading the fine line in ensuring that it achieves the profits it wants yet ensure that the tests remain affordable and accessible? 

On Under the Radar, Drive Time’s finance presenter Chua Tian Tian posed these burning questions to Dr Tan Min-Han Founder, CEO and Medical Director at Lucence.

Are you afraid of having your blood drawn? But what if the blood test could detect cancer causing genetic mutations and viruses, and allow for early treatment?  
I’m asking this because we are going to look at a company called Lucence, which makes blood tests to detect cancers. 
Founded in 2016, Lucence was spun off from the Agency for Science, Technology and Research (A*STAR). 
It had in 2019 unveiled a blood test called LiquidHALLMARK that detects 14 types of cancers, 50 genetic mutations and two viruses. Lucence had said then that LiquidHALLMARK is the world's first blood test that simultaneously detects both cancer-causing genetic mutations and viruses with 99.9 per cent accuracy.
But how much money does this represent? How does the company assess its competition, and how is it treading the fine line in ensuring that it achieves the profits it wants yet ensure that the tests remain affordable and accessible? 
On Under the Radar, Drive Time’s finance presenter Chua Tian Tian posed these burning questions to Dr Tan Min-Han Founder, CEO and Medical Director at Lucence.

Money Matters is your guide to navigating the day's most important topics, from politics and current affairs to wealth management and trending issues. Every evening, the team delivers insightful discussions on business news, market movements, and the latest in alternative assets. Whether navigating the political landscape, understanding the economy, or uncovering emerging investment opportunities, Money Matters keeps you informed and ahead of the curve. Tune in daily to Hongbin Jeong and Chua Tian Tian from 4 pm to 7 pm on MONEY FM 89.3.

Money Matters is your guide to navigating the day's most important topics, from politics and current affairs to wealth management and trending issues. Every evening, the team delivers insightful discussions on business news, market movements, and the latest in alternative assets. Whether navigating the political landscape, understanding the economy, or uncovering emerging investment opportunities, Money Matters keeps you informed and ahead of the curve. Tune in daily to Hongbin Jeong and Chua Tian Tian from 4 pm to 7 pm on MONEY FM 89.3.

Money Matters with Hongbin Jeong and Chua Tian Tian

Money Matters with Hongbin Jeong and Chua Tian Tian (4pm - 7pm)

Under the Radar: Lucence’s take on the global cancer diagnostics market surpassing US$258.54b by 2030, Its LiquidHALLMARK cancer detection blood test, treading the fine line between pricing products affordably and achieving business objectives

Advertisement